Drug safety advice
Combination use of medicines from different classes of renin-angiotensin system blocking agents is associated with an increased risk of hyperkalaemia, hypotension, and impaired renal function. New warnings have been agreed following an EU-wide review.
- Ferumoxytol: serious hypersensitivity reactions—reminder of precautions to take before and during administration
New data on serious hypersensitivity reactions following ferumoxytol administration are currently being reviewed by the European Medicines Agency. We remind you of the current measures to take to manage and minimise the risk of hypersensitivity reactions with any intravenous iron product.
Yellow Card Scheme update
With around 1 in 15 hospital admissions attributed to adverse drug reactions, a series of e-learning modules on adverse drug reactions was launched this month
- Ivabradine: emerging clinical trial evidence of increased cardiovascular risk—carefully monitor for bradycardia
Preliminary results have shown a small increase in the combined risk of cardiovascular death and non-fatal myocardial infarction with ivabradine compared with placebo in a subgroup of the SIGNIFY trial.
We have received reports of serious side effects in premature infants who were treated with chlorhexidine solution before central venous catheterisation.